{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bakker W"],"funding":["Novo Nordisk","European Research Council","Agence Nationale de la Recherche","National Institute of Diabetes and Digestive and Kidney Diseases","Horizon 2020 Framework Programme","Université de Paris","Centre National de la Recherche Scientifique","Fondation pour la Recherche Médicale","Boston Foundation for Architecture","H2020 Marie Skłodowska-Curie Actions"],"pagination":["111698"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9715912"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(8)"],"pubmed_abstract":["Therapies based on glucagon-like peptide-1 (GLP-1) long-acting analogs and insulin are often used in the treatment of metabolic diseases. Both insulin and GLP-1 receptors are expressed in metabolically relevant brain regions, suggesting a cooperative action. However, the mechanisms underlying the synergistic actions of insulin and GLP-1R agonists remain elusive. In this study, we show that insulin-induced hypoglycemia enhances GLP-1R agonists entry in hypothalamic and area, leading to enhanced whole-body fat oxidation. Mechanistically, this phenomenon relies on the release of tanycyctic vascular endothelial growth factor A, which is selectively impaired after calorie-rich diet exposure. In humans, low blood glucose also correlates with enhanced blood-to-brain passage of insulin, suggesting"],"journal":["Cell reports"],"pubmed_title":["Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis."],"pmcid":["PMC9715912"],"funding_grant_id":["ANR-15-CE14-0030-01","DK076169","810331","UMR 8251","748134","DK115255","ANR-17-CE37-0007-02"],"pubmed_authors":["Lundh S","Duquenne M","Salinas CG","Pedersen TA","Morel C","Maetzler W","Imbernon M","Luquet S","Castel J","Secher A","Martin C","Gangarossa G","Bakker W","Leger C","Denis RGP","Hecksher-Sorensen J","Moro Chao DH","Hassouna R","Peter A","Johan Hogendorf WF","Schwaninger M","Nielsen HS","Heni M","Prevot V"],"additional_accession":[]},"is_claimable":false,"name":"Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis.","description":"Therapies based on glucagon-like peptide-1 (GLP-1) long-acting analogs and insulin are often used in the treatment of metabolic diseases. Both insulin and GLP-1 receptors are expressed in metabolically relevant brain regions, suggesting a cooperative action. However, the mechanisms underlying the synergistic actions of insulin and GLP-1R agonists remain elusive. In this study, we show that insulin-induced hypoglycemia enhances GLP-1R agonists entry in hypothalamic and area, leading to enhanced whole-body fat oxidation. Mechanistically, this phenomenon relies on the release of tanycyctic vascular endothelial growth factor A, which is selectively impaired after calorie-rich diet exposure. In humans, low blood glucose also correlates with enhanced blood-to-brain passage of insulin, suggesting","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-22T01:54:43.948Z","creation":"2025-04-05T20:07:35.157Z"},"accession":"S-EPMC9715912","cross_references":{"pubmed":["36417883"],"doi":["10.1016/j.celrep.2022.111698"]}}